Tribune Therapeutics
Tribune Therapeutics is a preclinical biopharmaceutical company founded in 2020, focused on developing novel medicines to treat fibrosis regardless of the cause, tissue, or diagnosis. Their strategy targets natural mechanisms involved in fibrosis, particularly the CCN protein family, to produce strong anti-fibrotic effects. The company aims to stop the cycle of scar formation and organ failure caused by fibrosis.
Industries
biotechnology
pharmaceutical
therapeutics
Nr. of Employees
small (1-50)
Tribune Therapeutics
C/O Healthcap VIII Advisor Ab, Engelbrektsplan 1, 114 34 Stockholm
Products
Lead anti-fibrotic protein therapeutic (preclinical candidate)
A preclinical protein therapeutic designed to interfere with activated pro-fibrotic domains of CCN family proteins to block fibrotic signaling across tissues.
Lead anti-fibrotic protein therapeutic (preclinical candidate)
A preclinical protein therapeutic designed to interfere with activated pro-fibrotic domains of CCN family proteins to block fibrotic signaling across tissues.
Expertise Areas
- Anti-fibrotic drug discovery
- Protein therapeutic development
- Preclinical pharmacology and in vivo fibrosis models
- Biologics process development and CMC
Key Technologies
- Protein therapeutics
- Structure–function analysis
- Recombinant protein expression and production
- In vivo organ fibrosis models